// App-Quantinova.ai

: Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience

Researchers

Presenter

  • Vidhya Murthy

Principal Investigators

  • Nilupulee Kapuge

  • Charalampos Kartsios

  • Joanne Ewing

  • Evgenia Xenou

  • Maria Kaparou

  • Elmoamly Shereef

  • Emmanouil Nikolousis

Medical Centers

  • Heart of England NHS Foundation Trust, UHB, Birmingham, GBR

  • Heartlands Hospital, University Hospital Birmingham NHS Trust, Birmingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved